Last reviewed · How we verify
rhPSMA-7.3 (18F) Injection
rhPSMA-7.3 (18F) Injection is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging.
rhPSMA-7.3 (18F) Injection is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging. Used for Diagnostic imaging of prostate cancer.
At a glance
| Generic name | rhPSMA-7.3 (18F) Injection |
|---|---|
| Also known as | flotufolastat F18, No other interventions, radiohybrid PSMA-targeted PET imaging agent, Radioligand for PET CT scanning |
| Sponsor | Blue Earth Diagnostics |
| Drug class | Radiopharmaceutical |
| Target | PSMA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to PSMA, a protein overexpressed in prostate cancer cells, allowing for visualization of PSMA-positive lesions. This enables accurate diagnosis and staging of prostate cancer.
Approved indications
- Diagnostic imaging of prostate cancer
Common side effects
- Injection site reaction
- Nausea
- Vomiting
Key clinical trials
- Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy (PHASE3)
- Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment (NA)
- Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection (PHASE1, PHASE2)
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance (PHASE2)
- Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer (PHASE1)
- Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence (PHASE3)
- [18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer (NA)
- Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhPSMA-7.3 (18F) Injection CI brief — competitive landscape report
- rhPSMA-7.3 (18F) Injection updates RSS · CI watch RSS
- Blue Earth Diagnostics portfolio CI